Aromatase inhibitors (AIs), such as anastrozole, are extensively utilized in the treatment of estrogen receptor (ER)+/progesterone receptor (PgR)+ postmenopausal breast cancer patients, as AIs block paracrine production of growth stimulating hormones at the tumor-cell level (1,2). Here, ESR1 is linked to breast carcinoma.